Clinical trials of statins, widely-used drugs that inhibit the HMG-CoA reductase required for an upstream step in cholesterol biosynthesis, have been initiated on the basis of research showing that statin therapy reduced bacterial load within macrophages in vitro and in mice and that statins may function as adjuvant therapies for tuberculosis [59–61]. This evidence concerns the gene HMGCR and tuberculosis.